EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Informat...
April 19 2018 - 7:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
(ASX:PVA), a specialty biopharmaceutical company committed to
developing and commercializing innovative ophthalmic
products, will report results for its third quarter of fiscal year
2018 on Tuesday, May 8, 2018. Management will host a
conference call to review the results at 4:30 p.m. ET on
the same day.
The conference call may be accessed by dialing
(877) 312-7507 from the U.S. and Canada, or (631)
813-4828 from international locations. The conference ID is
1758647. A live webcast will be available on the Investor Relations
section of the corporate website
at http://www.eyepointpharma.com.
A replay of the call will be available
beginning May 8, 2018, at approximately 7:30 p.m.
ET and ending on May 15, 2018, at 11:59 p.m. ET. The
replay may be accessed by dialing (855) 859-2056 within
the U.S. and Canada or (404) 537-3406 from
international locations, Conference ID Number: 1758647. A replay of
the webcast will also be available on the corporate website during
that time.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (formerly pSivida
Corp.) (www.eyepointpharma.com), headquartered in Watertown, MA, is
a specialty biopharmaceutical company committed to developing
and commercializing innovative ophthalmic products in
indications with high unmet medical need to help improve the lives
of patients with serious eye disorders. The Company has developed
three of only four FDA-approved sustained-release treatments for
back-of-the-eye diseases. In addition, DEXYCU™ was approved
by the U.S. Food and Drug Administration (FDA) on February 9,
2018. DEXYCU, administered as a single intraocular dose at
the end of ocular surgery for the treatment of postoperative
inflammation, is the first and only FDA-approved intraocular
product with this indication. ILUVIEN® (fluocinolone
acetonide intravitreal implant), a micro-insert for diabetic
macular edema, licensed to Alimera Sciences, is currently sold
directly in the U.S. and several EU countries. Retisert®
(fluocinolone acetonide intravitreal implant), for posterior
uveitis, is licensed to and sold by Bausch & Lomb. The New Drug
Application (NDA) for our lead product candidate, YUTIQ™
micro-insert for the treatment of non-infectious uveitis affecting
the posterior segment of the eye, has been accepted for filing by
the FDA and is currently under standard review with a Prescription
Drug User Fee Act (PDUFA) date of November 5, 2018. The Company's
pre-clinical development program is focused on using its core
Durasert platform technology to deliver drugs to treat wet
age-related macular degeneration, glaucoma, osteoarthritis and
other diseases. To learn more about the Company, please
visit www.eyepointpharma.com and connect on Twitter, LinkedIn,
Facebook and Google+.
Contact
Barbara Ryan – Investorsbarbara@barbararyanadvisors.co
203-274-2825
Thomas Gibson – Mediatom@tomgibsoncommunications.com
201-476-0322
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024